Sound Bioventures
Sound Bioventures is a venture capital firm focused on investing in about-to-be clinical and clinical stage private companies in Europe and the USA. The firm supports the development of novel medicines that address significant unmet medical needs, particularly in specialty therapeutics areas. With a strong foundation in the Nordic biotech ecosystem, Sound Bioventures aims to leverage Scandinavian science to build companies and facilitate cross-Atlantic exchange of innovation, sector knowledge, and capital.
Sound Bioventures
Nordenskiöldsgatan 11a, 211 19 Malmö, Sweden; Strandvejen 125, DK-2900 Hellerup, Denmark
What We Do
Sound Bioventures provides strong mentorship and expertise on both scientific and operational levels to its portfolio companies, ensuring they have the support needed to navigate challenges and uncertainties in developing novel therapeutics.
Geographic Focus
Industry Focus
Portfolio
#Biopharmaceutical
Artax Biopharma is focused on transforming the treatment of T-cell-mediated diseases with its first-in-class, oral small molecule immunomodulating agent, AX-158.
#Biotechnology
#Biopharmaceutical
Breye Therapeutics is developing novel oral therapies for retinal vascular diseases, focusing on diabetic retinopathy and age-related macular degeneration.
#Biopharmaceutical
#Biopharmaceutical
Teitur Trophics is developing new treatments for neurodegenerative diseases, with a lead drug candidate TT-P34 advancing into clinical development.
#Biopharmaceutical
#Biopharmaceutical
VarmX is developing a life-saving blood-clotting product inspired by snake venom, aimed at patients on blood thinners.
#Biopharmaceutical
Key People
Managing Partner
Managing Partner
Managing Partner
Principal
Associate
Office Manager